Rare Diseases

CheckOrphan is the leading #news and information platform dedicated to #rarediseases and #orphandrugs

[Rare Diseases @CheckOrphan]

SL Science Unveils New Preclinical Data Demonstrating Potent γδ T Cell Activity Against Chemotherapy-Resistant Glioblastoma - For More Information Visit https://t.co/2frn4MxsAc @SLScience_SLBT #Glioblastoma #Rare_Diseases #Orphan_Drugs #Brain_Cancer

[Rare Diseases @CheckOrphan]

Children With Cystic Fibrosis on Kaftrio Maintain Lung Function After Reducing Airway-Clearance Treatments - For More Information Visit https://t.co/MHdIRbkIgi @VertexPharma #Cystic_Fibrosis #Kaftrio #Rare_Diseases #Orphan_Drugs #Lung_Diseases #Pediatric_Diseases

[Rare Diseases @CheckOrphan]

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma - For More Information Visit https://t.co/fkp4AQGP2T @Nuvectis #Glioma #Brain_cancer #Rare_Diseases #Cancer

[Rare Diseases @CheckOrphan]

Skylark Bio Expands Pipeline with First CNS Development Program, SKY-AS, Targeting UBE3A Restoration in Angelman Syndrome - For More Information Visit https://t.co/AXbVO1qxei #Skylark_Bio #UBE3A #Angelman_Syndrome #Rare_Diseases #Orphan_Drugs

[Rare Diseases @CheckOrphan]

Sarepta Therapeutics to Present New Real-World Data on Duchenne Muscular Dystrophy and Delandistrogene Moxeparvovec at NMSG 2026 - For More Information Visit https://t.co/OzAKVkMLlM @Sarepta #Duchenne #Rare_Diseases #DMD #Muscular_Dystrophy #Orphan_Drugs

[Rare Diseases @CheckOrphan]

Satellos Bioscience Receives FDA Clearance for Forazapadin FSHD Trial, Secures Up to US$5M in Non-Dilutive Funding - For More Information Visit https://t.co/sJqiuIz7D4 @SatellosBio #Rare_Diseases #FSHD #FDA #Facioscapulohumeral_Muscular_Dystrophy #Orphan_Drugs

[Rare Diseases @CheckOrphan]

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - For More Information Visit https://t.co/56N9Q03TlN @aTyrNews #Pulmonary_Sarcoidosis #Rare_Diseases #FDA

[Rare Diseases @CheckOrphan]

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus - For More Information Visit https://t.co/3VMtR6ZBe2 #Immunovant #Rare_Diseases #Orphan_Drugs #Cutaneous_Lupus_Erythematosus #CLE #Drug_Discovery

[Rare Diseases @CheckOrphan]

Positive Interim Data Shows Roche’s Sefaxersen Significantly Reduces Proteinuria in People with IgA Nephropathy - For More Information Visit https://t.co/IgwzXOjfTY #Rare_Diseases #Orphan_Drugs #IgAN @Roche #Sefaxersen #IgA_Nephropathy #Berger_Disease #kidney_Disease

[Rare Diseases @CheckOrphan]

AlphaRose Therapeutics Secures NIH SBIR Fast Track Grant to Advance Rosiphersen for the Treatment of Bain Syndrome - For More Information Visit https://t.co/lUvL4ICINW #AlphaRose_Therapeutics #Bain_Syndrome #NIH #Rare_Diseases #Orphan_Drugs #Drug_Research

[Rare Diseases @CheckOrphan]

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome - For More Information Visit https://t.co/gWjt2SZjTN @QuoinPharma #Rare_Diseases #FDA #Peeling_Skin_Syndrome #Skin_Disorders #Orphan_Drugs #Quoin

[Rare Diseases @CheckOrphan]

Pretzel Therapeutics Receives FDA Fast Track Designation for PX578 for the Treatment of POLG-Mediated Primary Mitochondrial Disorders - For More Information Visit https://t.co/eW5aG6pRHt #Rare_Diseases #FDA #POLG_Disease #Pretzel_Therapeutics #Orphan_Drugs

[Rare Diseases @CheckOrphan]

Aclipse Therapeutics and Cypress BioPharma Announce Agreement to Launch Phase 2 Study in Childhood Nephrotic Syndrome - For More Information Visit https://t.co/lAFf3hT8Qj #Aclipse_Therapeutics #Cypress_BioPharma #Nephrotic_Syndrome #Rare_Diseases #Orphan_Drugs

[Rare Diseases @CheckOrphan]

Otsuka Establishes Ulefnersen Early Access Program (EAP) for Eligible People Living with FUS-ALS - For More Information Visit https://t.co/GhPgtYogJD @OtsukaUS #FUS_ALS #ALS #Rare_Diseases #Amyotrophic_Lateral_Sclerosis #Orphan_Drugs #Lou_Gehrig_Disease

[Rare Diseases @CheckOrphan]

IMUNON’s Phase 2 IMNN-001 Study in Advanced Ovarian Cancer Cleared to Continue After IDMC Confirms Favorable Safety Profile - For More Information Visit https://t.co/tAYvWXmPEV #IMUNON #IDMC #Ovarian_Cancer #Rare_Diseases #Orphan_Drugs #Cancer_research

[Rare Diseases @CheckOrphan]

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy - For More Information Visit https://t.co/Mpi9w2rfqr #Filana_Therapeutics #Rare_diseases #FDA #Orphan_Drugs #Epilepsy #TSC_Related_Epilepsy #Simufilam

[Rare Diseases @CheckOrphan]

European Commission Approves Roche’s Susvimo® for the Treatment of Neovascular Age-Related Macular Degeneration (nAMD) - For More Information Visit https://t.co/UrWKijtMRg #nAMD #Eye_Disorders @Roche #Age_Related_Macular_Degeneration #Rare_Diseases #Orphan_Drugs

[Rare Diseases @CheckOrphan]

Otsuka and Ionis Announce Positive Phase 3 Results for Ulefnersen in FUS-ALS, Demonstrating Significant Benefits in Function and Survival - For More Information Visit https://t.co/q7wmiKVlVl @OtsukaUS #ALS @ionispharma #amyotrophic_lateral_sclerosis #Rare_Diseases #FUS_ALS

[Rare Diseases @CheckOrphan]

Vironexis Reports MRD-Negative Complete Responses in All Three R/R Acute Lymphoblastic Leukemia Patients Treated With Single-Dose VNX-101 - For More Information Visit https://t.co/c0CvNKXjI4 @vironexis #Leukemia #Acute_Lymphoblastic_Leukemia #Rare_Diseases #Orphan_Drugs

[Rare Diseases @CheckOrphan]

OS Therapies Advances Global OST-HER2 Access Pathway for Pulmonary Metastatic Osteosarcoma Under Project Orbis - For More Information Visit https://t.co/pGYbERENlc @OSTherapies #rare_Diseases #Bone_Cancer #Pulmonary_Metastatic_Osteosarcoma #Orphan_Drugs #OS_Therapies